{"schema_version":"secwatch.filing_event.v1","accession":"0001485003-23-000089","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.199163+00:00","generated_at":"2026-06-18T21:50:50.501235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sesen Bio reports Q4 net loss $7.6M; reiterates support for Carisma merger ahead of shareholder vote","bullets":["Q4 net loss $7.6M ($0.04/shr) vs net income $8.9M in Q4 2021; FY net loss $19.9M ($0.10/shr).","Cash, equivalents and marketable securities $166.9M as of Dec 31, 2022.","Board increased special cash dividend to $75M (~$0.36/shr) under amended merger with Carisma; CVR period extended to Mar 2027.","ISS and Glass Lewis recommend voting 'FOR' all merger proposals at Mar 2, 2023 special meeting.","Nasdaq granted exception from $1.00 bid price requirement to complete merger by Mar 10, 2023 or face delisting."],"urls":{"canonical":"https://secwatch.observer/filing/0001485003-23-000089","json":"https://secwatch.observer/filing/0001485003-23-000089.json","markdown":"https://secwatch.observer/filing/0001485003-23-000089.md","text":"https://secwatch.observer/filing/0001485003-23-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000089/0001485003-23-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000089/sesn-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:50:50.501235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e40f149557f768b19ef480fccf747bb9f54a830","claim":"Carisma Therapeutics Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000089/0001485003-23-000089-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}